Glucotrack, INC 10-Q quarterly reports

GlucoTrack reports Q1 2026 results amid going concern warnings and a pending Nasdaq delisting appeal.

Glucotrack, Inc. reported an increased net loss for Q3 2025, alongside positive first-in-human clinical trial results for its implantable continuous blood glucose monitor and ongoing efforts to secure future financing.

Glucotrack, Inc. reported progress in its implantable glucose monitor clinical trials and significant capital raises, but disclosed substantial doubt about its ability to continue as a going concern and identified material weaknesses in internal controls.

GlucoTrack Inc. announces its financial results for the first quarter of 2025, showcasing advancements in its Glucotrack CBGM development and ongoing efforts to secure funding.

GlucoTrack Inc. reported a net loss of $5.1 million for the third quarter of 2024, as it continues to develop its implantable continuous glucose monitor (CGM) technology.

Glucotrack Inc. reported its financial results for the second quarter of 2024, highlighting a significant increase in research and development expenses as it advances its implantable continuous glucose monitoring (CGM) technology.

GlucoTrack Inc. reported a significant increase in research and development expenses and a larger net loss for the first quarter of 2024 compared to the same period last year, while also addressing ongoing Nasdaq compliance issues.